Koustas Evangelos, Trifylli Eleni-Myrto, Sarantis Panagiotis, Papadopoulos Nikolaos, Aloizos Georgios, Tsagarakis Ariadne, Damaskos Christos, Garmpis Nikolaos, Garmpi Anna, Papavassiliou Athanasios G, Karamouzis Michalis V
Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens 11527, Greece.
1 Department of Internal Medicine, 417 Army Share Fund Hospital of Athens, Athens 11521, Attica, Greece.
World J Gastrointest Oncol. 2022 Sep 15;14(9):1665-1674. doi: 10.4251/wjgo.v14.i9.1665.
Colorectal cancer (CRC) constitutes the third most frequently reported malignancy in the male population and the second most common in women in the last two decades. Colon carcinogenesis is a complex, multifactorial event, resulting from genetic and epigenetic aberrations, the impact of environmental factors, as well as the disturbance of the gut microbial ecosystem. The relationship between the intestinal microbiome and carcinogenesis was relatively undervalued in the last decade. However, its remarkable effect on metabolic and immune functions on the host has been in the spotlight as of recent years. There is a strong relationship between gut microbiome dysbiosis, bowel pathogenicity and responsiveness to anti-cancer treatment; including immunotherapy. Modifications of bacteriome consistency are closely associated with the immunologic response to immunotherapeutic agents. This condition that implies the necessity of gut microbiome manipulation. Thus, creatingan optimal response for CRC patients to immunotherapeutic agents. In this paper, we will review the current literature observing how gut microbiota influence the response of immunotherapy on CRC patients.
在过去二十年中，结直肠癌（CRC）是男性人群中报告频率第三高的恶性肿瘤，在女性中则是第二常见的恶性肿瘤。结肠癌的发生是一个复杂的多因素事件，由遗传和表观遗传异常、环境因素的影响以及肠道微生物生态系统的紊乱导致。在过去十年中，肠道微生物群与致癌作用之间的关系相对被低估。然而，近年来，其对宿主代谢和免疫功能的显著影响受到了关注。肠道微生物群失调、肠道致病性与对抗癌治疗（包括免疫疗法）的反应之间存在密切关系。细菌群落组成的改变与对免疫治疗药物的免疫反应密切相关。这种情况意味着需要对肠道微生物群进行调控，从而为CRC患者对免疫治疗药物产生最佳反应。在本文中，我们将回顾当前文献，观察肠道微生物群如何影响CRC患者对免疫治疗的反应。
